StreetInsider.com News Articles

Rigel to present pralsetinib cancer data at ESMO Congress 2026

Mon, 19 Oct 2026 08:06:55 -0400

Rigel Pharmaceuticals (Nasdaq: RIGL) announced it will present clinical data on its drug GAVRETO (pralsetinib) at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, running October 23 to October 27, 2026.

A pooled analysis of 49 patients with RET fusion-positive solid tumors from the ARROW and TAPISTRY clinical trials, excluding non-small cell lung cancer (NSCLC) and thyroid tumors, showed an overall response rate (ORR) of 53% and a median duration of response of 12.2 months. Patients with previously treated pancreatic tumors had an ORR of 88% (7 of 8 patients).

In the TAPISTRY trial cohort of 16 response-evaluable patients

Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

Mon, 19 Oct 2026 08:05:00 -0400

Pooled ARROW and TAPISTRY analysis demonstrated a 53% overall response rate in patients with RET fusion-positive solid tumors
Additional analyses highlight first-line clinical outcomes and patient-reported quality of life in RET fusion-positive NSCLC and efficacy and safety in RET fusion-positive thyroid cancer

Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

Mon, 19 Oct 2026 08:05:00 -0400

Pooled ARROW and TAPISTRY analysis demonstrated a 53% overall response rate in patients with RET fusion-positive solid tumors
Additional analyses highlight first-line clinical outcomes and patient-reported quality of life in RET fusion-positive NSCLC and efficacy and safety in RET fusion-positive thyroid cancer

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 08:05:00 -0400

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 35,275 restricted stock units to 18 non-executive employees vesting

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 08:05:00 -0400

Rigel Pharmaceuticals (RIGL) PT Raised to $49 at Piper Sandler

Mon, 17 Aug 2026 07:43:56 -0400

Piper Sandler analyst Allison Bratzel raised the price target on Rigel Pharmaceuticals (NASDAQ: RIGL) to $49.00 (from $40.00) while maintaining a Neutral rating.

Rigel Pharmaceuticals (RIGL) PT Raised to $85 at H.C. Wainwright

Mon, 17 Aug 2026 06:45:59 -0400

H.C. Wainwright analyst Joseph Pantginis raised the price target on Rigel Pharmaceuticals (NASDAQ: RIGL) to $85.00 (from $57.00) while maintaining a Buy rating.

Form SCHEDULE 13G/A RIGEL PHARMACEUTICALS Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26926375.html

Form SCHEDULE 13G/A RIGEL PHARMACEUTICALS Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26926375.html

Form SCHEDULE 13G/A RIGEL PHARMACEUTICALS Filed by: Soleus Capital Master Fund, L.P.

Thu, 13 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26917416.html

Form SCHEDULE 13G/A RIGEL PHARMACEUTICALS Filed by: Soleus Capital Master Fund, L.P.

Thu, 13 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26917416.html

Rigel launches breast cancer drug Veppanu at $29,400 per month

Thu, 13 Aug 2026 08:05:40 -0400

Rigel Pharmaceuticals (NASDAQ: RIGL) announced that Veppanu (vepdegestrant) is now available by prescription in the United States for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy.

The drug, priced at $29,400 per 30-day supply, is available through specialty distributors and specialty pharmacies in the United States and Puerto Rico. The recommended dose is 200 mg taken orally once daily.

The FDA approved Veppanu in May 2026. The agency describes it as the first approved drug in the PROTAC (PROteolysis TArgeting Chimera) class, which works by degrading disease-causing proteins

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

Thu, 13 Aug 2026 08:05:00 -0400